Cargando…
Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189524/ https://www.ncbi.nlm.nih.gov/pubmed/34113549 http://dx.doi.org/10.21037/tcr.2020.02.42 |
| _version_ | 1783705515009769472 |
|---|---|
| author | Lyon, Kristopher A. Huang, Jason H. |
| author_facet | Lyon, Kristopher A. Huang, Jason H. |
| author_sort | Lyon, Kristopher A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8189524 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81895242021-06-09 Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial Lyon, Kristopher A. Huang, Jason H. Transl Cancer Res Editorial Commentary AME Publishing Company 2020-04 /pmc/articles/PMC8189524/ /pubmed/34113549 http://dx.doi.org/10.21037/tcr.2020.02.42 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Lyon, Kristopher A. Huang, Jason H. Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title | Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title_full | Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title_fullStr | Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title_full_unstemmed | Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title_short | Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial |
| title_sort | bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the aurelia trial |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189524/ https://www.ncbi.nlm.nih.gov/pubmed/34113549 http://dx.doi.org/10.21037/tcr.2020.02.42 |
| work_keys_str_mv | AT lyonkristophera bevacizumabcombinedwithchemotherapyinplatinumresistantovariancancerbeyondtheaureliatrial AT huangjasonh bevacizumabcombinedwithchemotherapyinplatinumresistantovariancancerbeyondtheaureliatrial |